WILFRED JEFFERIES
Chief Scientific Officer
Director and Chairman
DR WILFRED JEFFERIES
Chief Scientific Officer, Director and Chairman - BC, Canada
Dr. Wilfred Jefferies is a Professor at the University of British Columbia where he has been conducting research and mentoring students and post-doctoral researchers for over 25 years. He originally obtained his Bachelor of Science in Biochemistry from the University of Victoria and then moved to the University of Oxford in the United Kingdom to study at the Sir William Dunn School of Pathology, where he obtained his Doctor of Philosophy, focused on Molecular Pathology and Immunology. He subsequently completed post-doctoral research at the Institut Suisse de Recherches Expérimentales sur le Cancer in the L’École polytechnique fédérale de Lausanne (EPFL) in Switzerland and later conducted research at the Ludwig Institute for Cancer Research (LICR), in the Karolinska Institute in Stockholm, Sweden. Professor Jefferies is currently a Principal Investigator of the Michael Smith Laboratories at University of British Columbia, and the Vancouver Prostate Centre (VPC) at Vancouver General Hospital (VGH) where he is the Head of Immune Oncology. He is an author of over 100 peer reviewed manuscripts including pioneering studies discovering the interrelation between immune system escape and cancer progression as well as describing the link between blood brain barrier permeability and Alzheimer’s Disease. He is an inventor and patent holder of technologies that form the basis of several biotechnology companies currently active in Canada and the USA.
Dr. Jefferies has been inducted as a Fellow of the National Academy of Inventors, a non-profit organization with the mission to recognize and encourage academic invention. This honour is in recognition of his having created outstanding inventions that have made a positive impact on society.
See: "Cancer chemotherapy drug reverses Alzheimer’s symptoms in mice" (news)- Read paper: DOI http://dx.doi.org/10.1016/j.ebiom.2021.103503
- "Reversing pathology in a preclinical model of Alzheimer's disease by hacking cerebrovascular neoangiogenesis with advanced cancer therapeutics".
- Published in The Lancet, EBioMedicine Section, September 2021.